Vaginal Estradiol and Oral Guaifenesin in Clomiphene Ovulation Induction (NCT07398924) | Clinical Trial Compass
CompletedNot Applicable
Vaginal Estradiol and Oral Guaifenesin in Clomiphene Ovulation Induction
Turkey (Türkiye)90 participantsStarted 2022-01-06
Plain-language summary
Clomiphene citrate is commonly used for ovulation induction; however, it may negatively affect endometrial development and cervical mucus quality, which can reduce pregnancy rates. Various adjunctive treatments have been proposed to overcome these antiestrogenic effects.
This randomized clinical trial aimed to compare the effects of vaginal estradiol and oral guaifenesin, alone or in combination, on endometrial thickness, cervical mucus characteristics, and clinical pregnancy rates in women undergoing ovulation induction with clomiphene citrate.
A total of 90 women with infertility undergoing ovulation induction were randomly assigned to one of three treatment groups: clomiphene citrate plus guaifenesin, clomiphene citrate plus vaginal estradiol, or clomiphene citrate combined with both guaife
Who can participate
Age range
18 Years – 40 Years
Sex
FEMALE
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* \- Women aged 18 to 40 years
* Diagnosis of infertility
* Indication for ovulation induction with clomiphene citrate
* Regular or irregular menstrual cycles suitable for ovulation induction
* At least one patent fallopian tube
* Normal uterine cavity on ultrasonography
* Male partner with normal or mildly abnormal semen parameters
* Willingness to participate and provide informed consent
Exclusion Criteria:
* \- Known hypersensitivity to clomiphene citrate, guaifenesin, or estradiol
* Severe male factor infertility
* Presence of uterine anomalies or intrauterine pathology
* Endocrine disorders affecting ovulation (e.g., uncontrolled thyroid disease, hyperprolactinemia)
* Polycystic ovary syndrome requiring alternative stimulation protocols
* History of recurrent pregnancy loss
* Use of hormonal treatment within the last 3 months
Questions worth asking your doctor
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
Questions for the trial coordinator
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
What they're measuring
1
Clinical pregnancy rate
Timeframe: From ovulation trigger administration to confirmation of clinical pregnancy by transvaginal ultrasonography within the same treatment cycle (approximately 4-6 weeks).